Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025
Toronto, ON – Sept 18, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance.
The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in TempraMed’s history. August 2026 sales reached approximately US$403,000, representing the Company’s second-highest monthly sales result to date.
As a result of this performance, management expects Q3 2026 sales to be significantly stronger than Q3 2025, reflecting continued commercial momentum across TempraMed’s growing portfolio of medication temperature-protection products and expanding distribution channels.
For the eight-month period ended August 31, 2026, TempraMed recorded approximately US$2.07 million in sales, already exceeding the Company’s total sales for the full 2025 fiscal year of approximately US$1.8 million.
“We are excited to share these sales results for the last few months as it shows significant growth and adoption in 2026 so far. Because our next financing disclosure is not expected until November, we believe it is important to provide the market with visibility into our recent sales performance. July was a record month for TempraMed, August was our second-highest month to date, and our year-to-date sales have already surpassed total sales for all of last year,” said Ron Nagar, Chief Executive Officer of TempraMed.
“These results reflect growing market demand for our products and the early impact of our strategy to expand beyond direct-to-consumer sales into institutional, pharmacy, distributor and healthcare-system channels,” added Nagar. “While we remain focused on disciplined execution, the recent sales performance demonstrates that TempraMed is entering a new stage of commercial scale.”
TempraMed believes its growth is supported by several key drivers, including increased awareness of medication temperature exposure, broader adoption of temperature-sensitive injectable therapies such as insulin and GLP-1 medications, expanding product availability through healthcare and pharmacy channels, and the Company’s continued transition toward a more diversified B2B and institutional commercial model.
Management expects these trends to remain important drivers of TempraMed’s long-term growth strategy as the Company continues to expand access to its product portfolio across North America, Israel, Europe, Latin America, the Middle East and other target markets.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered thermal-insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™. TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime.
Investors interested in learning more about TempraMed are encouraged to contact the Company at:
Contact:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
Media:
Brenda Zeitlin
Vice President, Marketing
Cautionary Statements
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “strategy,” “will” and similar expressions, or statements concerning events or conditions that may occur in the future.
Forward-looking statements are based on the opinions, expectations and assumptions of management as of the date of this press release, including assumptions regarding receipt of required regulatory approvals, compliance by the distributor with the Agreement, availability of payment security, market acceptance of the private-label product, the distributor’s ability to commercialize the product through the contemplated retail channels, and continued demand for temperature-protection solutions for injectable medications.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied, including regulatory approval and import requirements, the possibility that purchase commitments may not be fulfilled, risks associated with Letter of Credit arrangements and collection of amounts due, changes in the intended retail or private-label commercialization strategy, competitive developments, market acceptance, general economic conditions, geopolitical risks, and other risks described in the Company’s public filings available on SEDAR+.
Except as required by applicable securities laws, the Company undertakes no obligation to update or revise publicly any forward-looking statements.
[1] https://humana.gcs-web.com